Prize to Weizmann Institute professor for landmark work in stem cell transplantation

December 16, 2002

Rehovot, Israel--December 16, 2002-- Prof. Yair Reisner of the Institute's Immunology Department was awarded the Daniele Chianelli Prize yesterday, commemorating his work of over 20 years on incompatible stem cell transplantation. Bone marrow or stem cell transplantation is a crucial part of the therapeutic strategy aimed at saving the lives of people with leukemia, malignant lymphoma, multiple myeloma and congenital blood disorders, such as halassemia or severe immune deficiencies.

Reisner's research, conducted in collaboration with a team led by Prof. Massimo Martelli of Italy's Perugia University has revolutionized transplantation therapy, enabling the transplant of partially matched stem cells in leukemia patients. Until recently, stem cell transplantations could only succeed if a full genetic match existed between the donor and recipient. Patients having no donor among their siblings had to search the general population, but for roughly half of them a matched donor was found too late or not at all.

The new approach by Reisner and Martelli, known as incompatible or haploidentical stem cell transplant requires that only three of six immunological markers be matched. Such a match is always present between parents and children, and there is a 75% chance of finding it among siblings. If the search includes the extended family, more than 95% of patients can find a donor. The achievements of the Perugia team and Prof. Reisner have aroused great interest in the scientific community. The researchers have made numerous presentations at international conferences and workshops and have published in leading scientific journals such as The New England Journal of Medicine, Science, Blood and Immunology Today. Nearly 150 patients throughout Europe have been treated using this approach, yielding significant success rates. The transplant procedure is well tolerated even in patients that are at high risk due to toxicity, advanced age, and disease stage (at least 50% of patients were transplanted in relapse of a leukemia that was resistant to all drugs).

The first mismatched transplant was attempted in 1993, in a 20-year-old factory worker from northern Italy, who had suffered from acute myeloid leukemia for a year, and had no matched donor in the family. As there was no time to search for an unrelated donor, physicians intended to perform an autologous transplant (using the patient's own stem cells), but by the time the transplant was ready, the patient's disease had relapsed. He underwent additional chemotherapy but failed to respond. By that time, his leukemia had progressed to a critical stage and infiltrated his liver and spleen. At the family's request, the Perugia team attempted a haploidentical transplant, using the patient's father as a donor.

Following a successful recovery, the patient was able to resume his normal lifestyle and returned to his job at the factory, where he still works today. Given the success of this first transplant the team attempted the second two months later in May 1993. This 36-year-old businessman had been suffering from acute myeloid leukemia for almost two years, had no compatible family donor. He had even been refused an unrelated donor from the international donor registries because his disease was so advanced that his condition left little room for hope. Then his 70-year-old mother volunteered to act as incompatible donor. Today he is in perfectly good health and has continued his successful career as an entrepreneur.

Encouraged by their success with their first two patients, the Perugia physicians went on to perform haploidentical transplants in nearly 150 other leukemia patients, by autumn 2002. Some of the patients who have been cured presented their stories at the award ceremony.
Prof. Reisner's research is supported by the Gabrielle Rich Leukemia Research Foundation, Switzerland; the M.D. Moross Institute for Cancer Research; the UBS Optimus Foundation, Switzerland; Mrs. Erica Drake, New York; the Ligue Nationale Francaise Contre Le Cancer, France; Mrs. Renee Companez, Australia; and Stanley A. Lewis, New York, NY. He holds the Henry H. Drake Professorial Chair in Immunology.

The Weizmann Institute of Science, in Rehovot, Israel, is one of the world's foremost centers of scientific research and graduate study. Its 2,500 scientists, students, technicians, and engineers pursue basic research in the quest for knowledge and the enhancement of humanity. New ways of fighting disease and hunger, protecting the environment, and harnessing alternative sources of energy are high priorities at Weizmann.

American Committee for the Weizmann Institute of Science

Related Stem Cells Articles from Brightsurf:

SUTD researchers create heart cells from stem cells using 3D printing
SUTD researchers 3D printed a micro-scaled physical device to demonstrate a new level of control in the directed differentiation of stem cells, enhancing the production of cardiomyocytes.

More selective elimination of leukemia stem cells and blood stem cells
Hematopoietic stem cells from a healthy donor can help patients suffering from acute leukemia.

Computer simulations visualize how DNA is recognized to convert cells into stem cells
Researchers of the Hubrecht Institute (KNAW - The Netherlands) and the Max Planck Institute in Münster (Germany) have revealed how an essential protein helps to activate genomic DNA during the conversion of regular adult human cells into stem cells.

First events in stem cells becoming specialized cells needed for organ development
Cell biologists at the University of Toronto shed light on the very first step stem cells go through to turn into the specialized cells that make up organs.

Surprising research result: All immature cells can develop into stem cells
New sensational study conducted at the University of Copenhagen disproves traditional knowledge of stem cell development.

The development of brain stem cells into new nerve cells and why this can lead to cancer
Stem cells are true Jacks-of-all-trades of our bodies, as they can turn into the many different cell types of all organs.

Healthy blood stem cells have as many DNA mutations as leukemic cells
Researchers from the Princess Máxima Center for Pediatric Oncology have shown that the number of mutations in healthy and leukemic blood stem cells does not differ.

New method grows brain cells from stem cells quickly and efficiently
Researchers at Lund University in Sweden have developed a faster method to generate functional brain cells, called astrocytes, from embryonic stem cells.

NUS researchers confine mature cells to turn them into stem cells
Recent research led by Professor G.V. Shivashankar of the Mechanobiology Institute at the National University of Singapore and the FIRC Institute of Molecular Oncology in Italy, has revealed that mature cells can be reprogrammed into re-deployable stem cells without direct genetic modification -- by confining them to a defined geometric space for an extended period of time.

Researchers develop a new method for turning skin cells into pluripotent stem cells
Researchers at the University of Helsinki, Finland, and Karolinska Institutet, Sweden, have for the first time succeeded in converting human skin cells into pluripotent stem cells by activating the cell's own genes.

Read More: Stem Cells News and Stem Cells Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to